MedTrace Logo

A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer

NCT03956654 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2024-08-09

No results posted yet for this study

Summary

The RibOB study is a prospective, open lable, single arm trial which will evaluate the clinical efficacy, overall safety and tolerability of ribociclib in combination with letrozole in older women (≥70 years) with HR+/HER2- aBC and no prior hormonal treatment for advanced disease (as per approved indication).

Conditions

Interventions

DRUG

Ribociclib

combination of ribociclib and letrozole

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Hans Wildiers, prof. dr. · UZ Gasthuisberg

Eligibility

Min Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-11
Primary Completion
2022-05-31
Completion
2024-06-30
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03956654 on ClinicalTrials.gov